Cargando…

Expressive language sampling as a source of outcome measures for treatment studies in fragile X syndrome: feasibility, practice effects, test-retest reliability, and construct validity

BACKGROUND: The evaluation of treatment efficacy for individuals with fragile X syndrome (FXS) or intellectual disability (ID) more generally has been hampered by the lack of adequate outcome measures. We evaluated expressive language sampling (ELS) as a procedure for generating outcome measures for...

Descripción completa

Detalles Bibliográficos
Autores principales: Abbeduto, Leonard, Berry-Kravis, Elizabeth, Sterling, Audra, Sherman, Stephanie, Edgin, Jamie O., McDuffie, Andrea, Hoffmann, Anne, Hamilton, Debra, Nelson, Michael, Aschkenasy, Jeannie, Thurman, Angela John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092603/
https://www.ncbi.nlm.nih.gov/pubmed/32204695
http://dx.doi.org/10.1186/s11689-020-09313-6
_version_ 1783510135865344000
author Abbeduto, Leonard
Berry-Kravis, Elizabeth
Sterling, Audra
Sherman, Stephanie
Edgin, Jamie O.
McDuffie, Andrea
Hoffmann, Anne
Hamilton, Debra
Nelson, Michael
Aschkenasy, Jeannie
Thurman, Angela John
author_facet Abbeduto, Leonard
Berry-Kravis, Elizabeth
Sterling, Audra
Sherman, Stephanie
Edgin, Jamie O.
McDuffie, Andrea
Hoffmann, Anne
Hamilton, Debra
Nelson, Michael
Aschkenasy, Jeannie
Thurman, Angela John
author_sort Abbeduto, Leonard
collection PubMed
description BACKGROUND: The evaluation of treatment efficacy for individuals with fragile X syndrome (FXS) or intellectual disability (ID) more generally has been hampered by the lack of adequate outcome measures. We evaluated expressive language sampling (ELS) as a procedure for generating outcome measures for treatment research in FXS. We addressed: (a) feasibility, (b) practice effects over two administrations, (c) test-retest reliability over the repeated administrations, and (d) construct validity. We addressed these issues for the full sample as well as for subgroups defined by age, IQ, and ASD status. METHODS: Participants were 106 individuals with FXS between ages 6 and 23 years who had IQs within the range of intellectual disability (IQ < 70). ELS procedures for collecting samples in conversation and narration were followed and analyzed separately. Five measures were derived from transcripts segmented into C-units (i.e., an independent clause and its modifiers): number of C-units per minute (talkativeness), number of different word roots (vocabulary), C-unit length in morphemes (syntax), percentage of C-units containing dysfluency (utterance planning), and percentage of C-units that were fully or partly unintelligible (articulatory quality). ELS procedures were administered twice at 4-week intervals for each participant. Standardized tests and informant reports were administered and provided measures for evaluating construct validity of ELS measures. RESULTS: We found low rates of noncompliance, suggesting the task can be completed meaningfully by most individuals with FXS, although noncompliance was higher for younger, lower IQ, and more autistic participants. Minimal practice effects and strong test-retest reliability over the 4-week interval were observed for the full sample and across the range of ages, IQs, and autism symptom severity. Evidence of convergent construct validity was observed for the measures of vocabulary, syntax, and unintelligibility for the full sample and across the range of IQ and autism symptom severity, but not for participants under age 12. Conversation and narration yielded largely similar results in all analyses. CONCLUSIONS: The findings suggest that the ELS procedures are feasible and yield measures with adequate psychometric properties for a majority of 6 to 23 years with FXS who have ID. The procedures work equally well regardless of level of ID or degree of ASD severity. The procedures, however, are more challenging and have somewhat less adequate psychometric properties for individuals with FXS under age 12.
format Online
Article
Text
id pubmed-7092603
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-70926032020-03-27 Expressive language sampling as a source of outcome measures for treatment studies in fragile X syndrome: feasibility, practice effects, test-retest reliability, and construct validity Abbeduto, Leonard Berry-Kravis, Elizabeth Sterling, Audra Sherman, Stephanie Edgin, Jamie O. McDuffie, Andrea Hoffmann, Anne Hamilton, Debra Nelson, Michael Aschkenasy, Jeannie Thurman, Angela John J Neurodev Disord Research BACKGROUND: The evaluation of treatment efficacy for individuals with fragile X syndrome (FXS) or intellectual disability (ID) more generally has been hampered by the lack of adequate outcome measures. We evaluated expressive language sampling (ELS) as a procedure for generating outcome measures for treatment research in FXS. We addressed: (a) feasibility, (b) practice effects over two administrations, (c) test-retest reliability over the repeated administrations, and (d) construct validity. We addressed these issues for the full sample as well as for subgroups defined by age, IQ, and ASD status. METHODS: Participants were 106 individuals with FXS between ages 6 and 23 years who had IQs within the range of intellectual disability (IQ < 70). ELS procedures for collecting samples in conversation and narration were followed and analyzed separately. Five measures were derived from transcripts segmented into C-units (i.e., an independent clause and its modifiers): number of C-units per minute (talkativeness), number of different word roots (vocabulary), C-unit length in morphemes (syntax), percentage of C-units containing dysfluency (utterance planning), and percentage of C-units that were fully or partly unintelligible (articulatory quality). ELS procedures were administered twice at 4-week intervals for each participant. Standardized tests and informant reports were administered and provided measures for evaluating construct validity of ELS measures. RESULTS: We found low rates of noncompliance, suggesting the task can be completed meaningfully by most individuals with FXS, although noncompliance was higher for younger, lower IQ, and more autistic participants. Minimal practice effects and strong test-retest reliability over the 4-week interval were observed for the full sample and across the range of ages, IQs, and autism symptom severity. Evidence of convergent construct validity was observed for the measures of vocabulary, syntax, and unintelligibility for the full sample and across the range of IQ and autism symptom severity, but not for participants under age 12. Conversation and narration yielded largely similar results in all analyses. CONCLUSIONS: The findings suggest that the ELS procedures are feasible and yield measures with adequate psychometric properties for a majority of 6 to 23 years with FXS who have ID. The procedures work equally well regardless of level of ID or degree of ASD severity. The procedures, however, are more challenging and have somewhat less adequate psychometric properties for individuals with FXS under age 12. BioMed Central 2020-03-24 /pmc/articles/PMC7092603/ /pubmed/32204695 http://dx.doi.org/10.1186/s11689-020-09313-6 Text en © The Author(s) 2020, corrected publication 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Abbeduto, Leonard
Berry-Kravis, Elizabeth
Sterling, Audra
Sherman, Stephanie
Edgin, Jamie O.
McDuffie, Andrea
Hoffmann, Anne
Hamilton, Debra
Nelson, Michael
Aschkenasy, Jeannie
Thurman, Angela John
Expressive language sampling as a source of outcome measures for treatment studies in fragile X syndrome: feasibility, practice effects, test-retest reliability, and construct validity
title Expressive language sampling as a source of outcome measures for treatment studies in fragile X syndrome: feasibility, practice effects, test-retest reliability, and construct validity
title_full Expressive language sampling as a source of outcome measures for treatment studies in fragile X syndrome: feasibility, practice effects, test-retest reliability, and construct validity
title_fullStr Expressive language sampling as a source of outcome measures for treatment studies in fragile X syndrome: feasibility, practice effects, test-retest reliability, and construct validity
title_full_unstemmed Expressive language sampling as a source of outcome measures for treatment studies in fragile X syndrome: feasibility, practice effects, test-retest reliability, and construct validity
title_short Expressive language sampling as a source of outcome measures for treatment studies in fragile X syndrome: feasibility, practice effects, test-retest reliability, and construct validity
title_sort expressive language sampling as a source of outcome measures for treatment studies in fragile x syndrome: feasibility, practice effects, test-retest reliability, and construct validity
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092603/
https://www.ncbi.nlm.nih.gov/pubmed/32204695
http://dx.doi.org/10.1186/s11689-020-09313-6
work_keys_str_mv AT abbedutoleonard expressivelanguagesamplingasasourceofoutcomemeasuresfortreatmentstudiesinfragilexsyndromefeasibilitypracticeeffectstestretestreliabilityandconstructvalidity
AT berrykraviselizabeth expressivelanguagesamplingasasourceofoutcomemeasuresfortreatmentstudiesinfragilexsyndromefeasibilitypracticeeffectstestretestreliabilityandconstructvalidity
AT sterlingaudra expressivelanguagesamplingasasourceofoutcomemeasuresfortreatmentstudiesinfragilexsyndromefeasibilitypracticeeffectstestretestreliabilityandconstructvalidity
AT shermanstephanie expressivelanguagesamplingasasourceofoutcomemeasuresfortreatmentstudiesinfragilexsyndromefeasibilitypracticeeffectstestretestreliabilityandconstructvalidity
AT edginjamieo expressivelanguagesamplingasasourceofoutcomemeasuresfortreatmentstudiesinfragilexsyndromefeasibilitypracticeeffectstestretestreliabilityandconstructvalidity
AT mcduffieandrea expressivelanguagesamplingasasourceofoutcomemeasuresfortreatmentstudiesinfragilexsyndromefeasibilitypracticeeffectstestretestreliabilityandconstructvalidity
AT hoffmannanne expressivelanguagesamplingasasourceofoutcomemeasuresfortreatmentstudiesinfragilexsyndromefeasibilitypracticeeffectstestretestreliabilityandconstructvalidity
AT hamiltondebra expressivelanguagesamplingasasourceofoutcomemeasuresfortreatmentstudiesinfragilexsyndromefeasibilitypracticeeffectstestretestreliabilityandconstructvalidity
AT nelsonmichael expressivelanguagesamplingasasourceofoutcomemeasuresfortreatmentstudiesinfragilexsyndromefeasibilitypracticeeffectstestretestreliabilityandconstructvalidity
AT aschkenasyjeannie expressivelanguagesamplingasasourceofoutcomemeasuresfortreatmentstudiesinfragilexsyndromefeasibilitypracticeeffectstestretestreliabilityandconstructvalidity
AT thurmanangelajohn expressivelanguagesamplingasasourceofoutcomemeasuresfortreatmentstudiesinfragilexsyndromefeasibilitypracticeeffectstestretestreliabilityandconstructvalidity